-
EAU24 Interview丨Dr. Junlong Zhuang and Dr. Bertrand Tombal jointly interpret the ARASENS study and explore intensive treatment strategies for mHSPC
Dr. Junlong Zhuang Drum Tower hospital Dr. Bertrand Tombal Université Catholique de Louvain (UCL) Oncology Frontier: Good morning, Dr. Tombal. The ARASENS study has demonstrated that the combination of ADT…
-
EAU24 Interview | Dr. Jens Bedke：Innovations in Advanced Urothelial Carcinoma Treatment
Dr. Jens Bedke Klinikum Stuttgart Katharinen Hospital Urology Frontier：Currently, platinum-based combination chemotherapy is still the first-line standard treatment for advanced urothelial carcinoma（UC）. What unmet needs do you think exist for…
-
EAU24 Interview丨Dr. Vasileios Sakalis：The value of artificial intelligence in the diagnosis and treatment of urinary tumors
Vasileios Sakalis MSc, PhD, FEBU, FRCS Consultant at Hippokration General Hospital, Thessaloniki Oncology Frontier：How accurate do you think current AI is in the field of urological cancers? Dr. Vasileios Sakalis:…
-
EBMT Distinguished Interview | Professor Jun Ma Reflects on 42 Years with EBMT
From April 14 to 17, 2024, the 50th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) was grandly held in Glasgow, UK. This year marks the 50th anniversary of EBMT, and the event brought together leaders in the field of hematopoietic stem cell transplantation and over 6,000 hematology experts from around…
-
Professor Jianmin Ma: Research Progress on Ocular Adnexal Lymphoma | Inaugural Academic Forum of Ocular Lymphoma Collaboration Group
On March 30, 2024, the inaugural academic forum of the Ocular Lymphoma Collaboration Group was successfully held in Beijing, hosted by Peking University Health Science Center affiliated Beijing Tongren Hospital, the China Health Science and Technology Promotion Association, Beijing Public Health Science Popularization Association, and the Beijing Chen Jumei Public Welfare Foundation. The event, organized…
-
Professor Yi Luo: Interpretation of the Chinese Expert Consensus on Prevention and Treatment of Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation (2023 Edition)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a primary treatment for malignant blood diseases, with its numbers increasing annually. China is a region with moderate prevalence of hepatitis B virus (HBV), with approximately 5% to 6% of the population carrying hepatitis B surface antigen (HBsAg), and an annual incidence rate of about 1%. Patients positive…
-
2024 EBMT 5 Minutes | Professor Pan Jing: Advances in Acute Lymphoblastic Leukemia Research
The European Society for Blood and Marrow Transplantation (EBMT) annual meeting is one of the most influential international academic conferences in the field of hematology. The 50th EBMT annual meeting (EBMT 2024) was held from April 14 to April 17 in Glasgow, UK, bringing together nearly 6,000 experts and scholars from around the world to…
-
EBMT 2024 | Entering the Golden Age – Grand Opening of the 50th European Society for Blood and Marrow Transplantation Annual Meeting
From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in the renowned city of Glasgow, United Kingdom. This year marks the 50th anniversary of EBMT’s establishment, and the conference brought together leading figures in the field of hematopoietic stem cell transplantation, along…
Connecting Medical Expertise through Media